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OBJECTIVE — The purpose of this study was to identify predictors of incident diabetes
during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in
Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.
RESEARCHDESIGNANDMETHODS — Atotalof1,620nondiabeticpatientshadfull
baseline datasets. We compared baseline demographic, medication, and laboratory data for
patients who did or did not develop diabetes and conducted logistic regression and receiver
operator characteristic curve analyses.
RESULTS — Over a median period of 2.8 years, 126 of the 1,620 patients (7.8%) developed
diabetes. In multiple logistic regression analysis, the following baseline characteristics were
independently associated with incident diabetes in decreasing order of signiﬁcance by stepwise
selection:higherA1C(oddsratio[OR]1.78per1SDincrease;P0.0001),higherBMI(OR1.64
per 1 SD increase; P  0.0001), lipid-lowering therapy (OR 2.05; P  0.0005), lower serum
creatinine concentration (OR 0.68 per 1 SD increase; P  0.0018), diuretic therapy (OR 4.81;
P  0.003), digoxin therapy (OR 1.65; P  0.022), higher serum alanine aminotransferase
concentration(OR1.15per1SDincrease;P0.027),andlowerage(OR0.81per1SDincrease;
P  0.048). Using receiver operating characteristic curve analysis, A1C and BMI yielded areas
underthecurveof0.723and0.712,respectively,increasingto0.788whencombined.Addition
ofothervariablesindependentlyassociatedwithdiabetesriskminimallyimprovedpredictionof
diabetes.
CONCLUSIONS — In nondiabetic patients with CHF in CHARM, A1C and BMI were the
strongest predictors of the development of diabetes. Other minor predictors in part reﬂected
CHF severity or drug-associated diabetes risk.
Identifying patients with CHF at risk of diabe-
tes through simple criteria appears possible
and could enable targeted preventative
measures.
Diabetes Care 32:915–920, 2009
D
iabetes and chronic heart failure
(CHF) often coexist in patients (1).
The prevalence of diabetes in pa-
tients with CHF is substantial, typically
20–30% in clinical trials (1). Although
cautionshouldbeexercisedinextrapolat-
ing from these data, the prevalence ap-
pears substantially higher than that in the
general population. Furthermore, diabe-
tes is itself a well-recognized risk factor
for the development of CHF (1,2). When
diabetes is present in patients with CHF,
itisassociatedwithcomplicationssuchas
increased hospitalization (3), and diabe-
tes is also an independent predictor of
cardiovascularmorbidityandmortalityin
heart failure (4). It is therefore plausible,
although unproven, that approaches to
reduce incident diabetes in CHF may
have beneﬁts in such patients.
Strongpredictorsofdiabetesinthegen-
eral population are well established and in-
clude the following: 1) measures of
adiposity (5) such as BMI, waist circumfer-
ence, and waist-to-hip ratio (typically with
anareaunderthereceiveroperatingcharac-
teristic curve [AUC-ROC] 0.66–0.73); 2)
dysglycemia measures demonstrated by ei-
ther abnormal fasting or postload glucose
measures(AUC-ROC0.73–0.77)(6),orel-
evatedA1C,amarkerofcumulativeglucose
exposure (7,8); 3) combinations of mea-
suresofobesityanddysglycemia(9);and4)
risk scores or questionnaires such as the
CambridgeDiabetesRiskScore(10),which
combines age, sex, BMI, history of antihy-
pertensiveorsteroidmedication,familyhis-
tory,andsmokinghistorytoestimateriskof
diabetes (0.80).
AnalysisofdatafromtheCandesartan
in Heart Failure-Assessment of Reduction
in Mortality and Morbidity (CHARM)
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the incidence of diabetes in patients with
CHF treated with the angiotensin II re-
ceptor blocker (ARB) candesartan (11).
Whereas data on the rate of development
of CHF in diabetes are widely available,
there is no published evidence regarding
potential predictors of incident diabetes
in CHF. In this study we investigated
which characteristics were associated
with development of diabetes in patients
with CHF using data from the CHARM
program. Such data are novel and may be
of value in predicting those with an ele-
vated risk of diabetes and therefore help
improve targeting of preventative mea-
sures, if applicable.
RESEARCH DESIGN AND
METHODS— Detailed descriptions
ofthemethodsandresultsoftheCHARM
program have been published previously
(12–15). In brief, the CHARM program
consistedofthreeparalleltrialswithcom-
plementary populations of patients with
symptomatic CHF: 1) CHARM Alterna-
tive: left ventricular ejection fraction
(LVEF)0.40andpriorintolerancetoan
ACE inhibitor; 2) CHARM Added: LVEF
0.40 and receiving an ACE inhibitor al-
ready; and 3) CHARM Preserved: LVEF
0.40, whether or not already receiving
an ACE inhibitor.
A total of 7,601 (7,599 with data) pa-
tients were randomly assigned, of whom
2,163 were already known to have diabe-
tes, as reported by the investigators at the
time of randomization, a prevalence of
28.5%. In North America, 2,743 patients
were recruited, of whom 1,722 patients
werenotdiabeticand1,021werediabetic
at baseline (prevalence of 37.2%). Com-
plete datasets were deﬁned as datasets for
patients that contained all baseline demo-
graphic and clinical data, information re-
garding baseline drug therapies, and all
blood results and randomization data (as
in Table 1). Only the North American pa-
tients had blood samples analyzed for full
laboratory result sets via a central core fa-
cility, including A1C, at baseline. Of the
1,722 nondiabetic patients, complete
datasets were available for 1,620 patients,
and their data were analyzed in this re-
port; missing data were almost exclu-
sively missing laboratory data.
InCHARM,patientswererandomlyas-
signed to receive either candesartan or pla-
cebo. Patients received the study drug in
incremental doses (up to a maximum of 32
mg candesartan once daily as tolerated) or
matching placebo. Patients were followed
Table 1—Baseline characteristics of the 1,620 North American patients with full core
laboratory datasets in CHARM with no medical history of diabetes at baseline, grouped by
those who did and did not develop diabetes during the trials
No diabetes during trials Diabetes during trials
All patients 1,494 (92.2) 126 (7.8)
Age (years) 66.4  12.0 61.5  12.3
Sex (% male) 1,008 (67.5) 82 (65.1)
BMI (kg/m
2) 28.2  5.9 32.4  6.2
Smoking habit
Nonsmoker 451 (30.2) 38 (30.2)
Previous smoker 804 (53.8) 73 (57.9)
Current smoker 239 (16.0) 15 (11.9)
SBP (mmHg) 127  19 130  19
History of prior myocardial infarction 763 (51.1) 59 (46.8)
History of hypertension 915 (61.2) 85 (67.5)
NYHA class
II 600 (40.2) 45 (35.7)
III 860 (57.6) 78 (61.9)
IX 34 (2.3) 3 (2.4)
LVEF 0.38  0.2 0.36  0.2
Drug therapy
ACE inhibitors 636 (42.6) 62 (49.2)
-Blocker 791 (52.9) 80 (63.5)
Diuretic therapy 1,235 (82.7) 122 (96.8)
Long-acting nitrates 380 (25.4) 25 (19.8)
Spironolactone 215 (14.4) 27 (21.4)
Digoxin 766 (51.3) 82 (65.1)
Calcium channel blocker 353 (23.6) 30 (23.8)
Lipid-lowering drug 670 (44.8) 69 (54.8)
Oral anticoagulant 484 (32.4) 36 (28.6)
Laboratory results
A1C (%) 6.2  0.7 6.8  0.9
Creatinine (mol/l) 100  35 91  26
Potassium (mmol/l) 4.4  0.4 4.3  0.4
Sodium (mmol/l) 141  3 140  3
ALT (units/l) 18 (13–25) 23 (16–33)
AST (units/l) 20 (16–25) 20 (17–26)
Alkaline phosphatase (units/l) 79 (65–97) 85.5 (69–106)
Bilirubin total (mol/l) 10.0 (6.8–13.7) 10.3 (8.0–12.0)
Bilirubin direct (mol/l) 2.0 (1.7–4.0) 2.0 (1.7–3.4)
Hemoglobin (mmol/l) 8.5  1.0 8.6  0.8
Hematocrit (%) 41.2  4.6 41.5  3.7
Red cell count (10
12/l) 4.5  0.5 4.6  0.5
MCV (ﬂ) 92.6  5.9 91.2  5.3
MCH (pg) 30.9  2.4 30.5  2.0
MCHC (mmol/l) 20.7  0.7 20.8  0.7
White cell count (10
9/l) 7.1  2.1 7.6  2.1
Eosinophils (%) 2.7 (1.7–4.1) 2.5 (1.6–3.4)
Lymphocytes (%) 25.8  8.6 26.8  8.4
Basophils (%) 0.3 (0.2–0.5) 0.3 (0.2–0.6)
Neutrophils (%) 63.9  9.5 63.5  9.5
Neutrophils band (%) 1 (0–3) 0.5 (0–1)
Monocytes (%) 6.7  2.7 6.6  2.4
Treatment randomization
Candesartan 751 (50.3) 54 (42.9)
Data are means  SD, n (%), or median (interquartile range). AST, aspartate aminotransferase; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular
volume; NYHA, New York Heart Association Classiﬁcation of heart failure; SBP, systolic blood pressure.
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then every 4 months until the end of the
program. All patients provided written in-
formed consent, and the protocol was ap-
proved by the ethics committee at each
participating institution. A1C was mea-
sured in the central core laboratory on an
automated high-performance liquid chro-
matography analyzer (Bio-Rad Variant An-
alyzer; GMI, Ramsey, MN) using a Diabetes
Control and Complications Trial–aligned
assay. The upper limit of normal for the as-
say was quoted as 6.5%.
Diagnosis of diabetes
Investigators were asked to report the oc-
currence of a new diagnosis of diabetes for
all patients at the end of the trials. Fasting
blood tests were not performed as part of
the CHARM program, and formal tests for
diabeteswerenotdone.Detailsofdiagnoses
of diabetes (date of diagnosis, details of the
criteria for diagnosis, hypoglycemic medi-
cation prescribed, and lifestyle modiﬁca-
tions prescribed) during the study were
documented on case report forms at the
closing study visit as described previously
based on reporting by investigators (11).
Diagnosesofdiabeteswerebasedonfasting
plasma glucose 7 mmol/l (126 mg/dl),
2-h oral glucose tolerance tests (OGTTs) or
a random glucose 11.1 mmol/l (200
mg/dl),ordoctordiagnosisofdiabeteswith
treatment speciﬁcation. At baseline and
throughout the program, physicians were
freetoprescribevarioustreatments,includ-
ing other cardiovascular drugs (other than
ARBs)orglucose-loweringdrugs.Although
thedevelopmentofdiabeteswasaprespeci-
ﬁed outcome in CHARM, potential predic-
tors of diabetes were not prespeciﬁed.
Results are presented to allow comparison
of all pertinent or potentially relevant char-
acteristics between patients who did and
did not develop diabetes.
Statistical methods
Allvariablesmeasuredwereconsideredas
possible predictors of diabetes. We chose
this fully inclusive method because there
is little prior information on the range of
parameters potentially relevant to diabe-
tes risk in a population with CHF. Uni-
variate and multiple logistic regressions
were carried out to identify those vari-
ables associated with the development of
diabetes. For multiple logistic regression,
two methods were used: multiple logistic
regression including only those associa-
tions with P  0.10 on univariate logistic
regression and, as an additional check
given the large number of parameters
identiﬁed as potentially relevant, a for-
ward-backward stepwise selection pro-
cess. The forward-backward selection
procedure starts with estimating an inter-
cept for the model, followed by a forward
selection step. In this step the score 
2
statistic for each of the considered factors
not yet included in the model is com-
puted.Iftheeffectwiththelargeststatistic
issigniﬁcantataprespeciﬁedentrysignif-
icance level, the corresponding factor is
added to the model. This is followed by a
backward selection step. In this step, pa-
rameters for the complete model, as spec-
iﬁedafterthepreviousstep,areestimated.
The least signiﬁcant factor that does not
meet a prespeciﬁed signiﬁcance level is
removed. The backward selection step is
repeated until no factor is removed. The
forward step is then repeated and fol-
lowed by one or more backward elimina-
tion steps. The selection process terminates
if no further factor can be added or if the
factor just entered is the only factor re-
moved in the subsequent backward elimi-
nation. The odds ratios (ORs) and 95% CIs
comparing treatment groups were calcu-
lated for the overall data. For the purposes
of estimating diabetes predictive power,
AUC-ROC analysis was used in a stepwise
mode, with the AUC-ROC reported at each
step in the selection process.
RESULTS— During the CHARM pro-
gram, 365 (6.7%) of the 5,436 initially
nondiabetic patients developed diabetes.
This equates to an incidence of 21.4
cases per 1,000 patients per year. For the
1,620 patients with full datasets, i.e.,
those that are the subject of this report,
median follow-up was 2.8 years and dur-
ing this time 126 (7.8%) developed dia-
betes, an incidence of 27.8 cases per
1,000patientsperyear.Newdiagnosesof
diabetes were made as follows: 78 (62%)
from fasting glucose values, 7 (6%) from
OGTT,5(4%)fromacombinationoffast-
ing glucose and OGTT, and 36 (29%) for
whom no speciﬁc criteria were noted on
the case report forms. Median follow-up
for those who did not develop diabetes
(n  1,494) during the study was 2.8
years compared with 3.1 years for those
who did. Baseline characteristics of the
1,620 patients who did and did not de-
velop diabetes over the course of the
study are displayed in Table 1.
Univariate associations with
incident diabetes
The following baseline parameters
showed signiﬁcant positive associations
with the development of diabetes in uni-
variate logistic regression at baseline (in
decreasing order of signiﬁcance by Wald

2 statistic) (Table 2): higher A1C, higher
BMI, lower age, diuretic therapy, digoxin
therapy, lower serum creatinine concen-
tration, lower serum potassium, lower
meancorpuscularvolume,higherredcell
count, -blocker therapy, higher white
cell count, lipid-lowering therapy, spi-
ronolactone therapy, lower mean corpus-
cular hemoglobin, higher serum alanine
aminotransferase (ALT) concentration,
lower serum sodium concentration, and
lower eosinophil percentage. BMI was
split into quartiles which showed that in-
cident diabetes increased in a linear fash-
ion and therefore analyzing BMI as a
continuous variable was appropriate
(data not shown). A1C (Wald 
2 statistic
58.8) and BMI (Wald 
2 statistic 52.7)
were statistically the strongest predictors
in this analysis by some margin. Ex-
pressed per unit change, an increase in
A1C of 1% was associated with an in-
creased OR for incident diabetes of 2.30
(95% CI 1.86–2.84) and an increase in
BMI of 1 kg/m
2 was associated with an
increasedORforincidentdiabetesof1.10
(1.07–1.13). Expressed per SD, ORs for
incident diabetes were 1.79 (1.54–2.08)
and 1.78 (1.53–2.09) for increases of 1
SD in A1C and BMI, respectively. Those
with BMI 28 kg/m
2 were 4.29 (2.79–
6.61) times more likely to develop diabe-
tes and those aged 67 years were 60%
less likely to develop diabetes (OR 0.39
[95% CI 0.27–0.58]).
Independent predictors of incident
diabetes
Those characteristics associated with the
development of diabetes in univariate lo-
gisticregression(P0.10)wereincorpo-
rated into a multiple logistic regression
model (Table 2). The following baseline
characteristics showed signiﬁcant posi-
tive associations in decreasing order of
signiﬁcance:higherA1C,higherBMI,lip-
id-lowering therapy, lower serum creati-
nine concentration, diuretic therapy,
higher serum ALT concentration, and
digoxintherapy.Theindependentassoci-
ationsofhigherA1C,higherBMI,anduse
of lipid-lowering therapy with incident
diabetes were highly signiﬁcant (P 
0.001). Using the forward-backward
stepwise selection method of multiple lo-
gistic regression, with the prespeciﬁed
signiﬁcance level for entering and keep-
ing factors in the model set to 0.05, the
following parameters showed indepen-
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increased risk of developing diabetes (in
decreasing order of signiﬁcance) (Table
3): higher A1C, higher BMI, lipid-
lowering therapy, lower serum creatinine
concentration, diuretic therapy, digoxin
therapy, higher serum ALT concentra-
tion, and younger age. The two methods
of statistical analysis therefore identiﬁed
the same independent predictors of dia-
betes. Expressed per unit change, an in-
crease in A1C of 1% was associated with
an increased OR for incident diabetes of
2.28 (95% CI 1.82–2.85) and an increase
in BMI of 1 kg/m
2 was associated with an
increasedORforincidentdiabetesof1.09
(1.05–1.12). Expressed per SD, ORs for
incident diabetes were 1.78 (1.52–2.08)
and 1.64 (1.36–1.98), respectively, for
increases of 1 SD in A1C and BMI.
Assessing predictive ability of
baseline parameters for diabetes
AUC-ROC for A1C alone was 0.72. The
optimal point for prediction of diabetes
was at an A1C of 6.5%, which yielded a
sensitivity of 0.63 and speciﬁcity of 0.70.
Table 2—Baseline characteristics associated with the development of diabetes in CHARM as analyzed by univariate and multiple logistic
regression analyses
Univariate logistic regression Multiple logistic regression*
Wald 
2 P OR (95% CI) Wald 
2 P OR (95% CI)
A1C (per %) 58.8 0.0001 2.30 (1.86–2.84) 43.9 0.0001 2.20 (1.74–2.78)
BMI (per kg/m
2) 52.7 0.0001 1.10 (1.07–1.13) 24.7 0.0001 1.09 (1.05–1.12)
Age (per year) 19.0 0.0001 0.97 (0.96–0.98) 1.3 0.25 0.99 (0.97–1.01)
Diuretics at baseline (yes vs. no) 13.1 0.0003 6.39 (2.34–17.46) 6.9 0.008 4.17 (1.44–12.05)
Digoxin (yes vs. no) 8.7 0.003 1.77 (1.21–2.59) 5.9 0.016 1.73 (1.11–2.69)
Creatinine (per mol/l) 8.5 0.004 0.99 (0.98–1.00) 8.6 0.003 0.99 (0.98–1.00)
Potassium (per mmol/l) 8.2 0.004 0.53 (0.34–0.82) 3.3 0.07 0.63 (0.39–1.04)
MCV (per fL) 7.4 0.007 0.96 (0.93–0.99) 0.9 0.34 0.96 (0.89–1.04)
Red cell count (per 10
12/l) 5.7 0.02 1.53 (1.08–2.18) 0.0 0.97 1.01 (0.65–1.57)
-Blocker (yes vs. no) 5.1 0.02 1.55 (1.06–2.25) 3.6 0.06 1.50 (0.99–2.27)
White cell count (per 10
9/l) 5.1 0.02 1.09 (1.01–1.18) 0.1 0.75 0.99 (0.90–1.08)
Lipid-lowering therapy (yes vs. no) 4.6 0.03 1.49 (1.03–2.15) 12.8 0.0003 2.12 (1.41–3.20)
Spironolactone (yes vs. no) 4.5 0.03 1.62 (1.04–2.54) 1.3 0.25 1.35 (0.81–2.23)
MCH (per pg) 4.4 0.04 0.92 (0.85–1.00) 0.2 0.64 1.04 (0.87–1.25)
ALT (per units/l) 4.3 0.04 1.01 (1.00–1.02) 6.0 0.015 1.01 (1.00–1.02)
Sodium (per mmol/l) 3.9 0.048 0.94 (0.89–1.00) 0.7 0.41 0.97 (0.91–1.04)
Eosinophils (per %) 3.9 0.049 0.91 (0.83–1.00) 2.5 0.12 0.91 (0.81–1.02)
Candesartan therapy (placebo vs.
candesartan)
2.5 0.11 1.35 (0.93–1.95)
ACE inhibitors (yes vs. no) 2.1 0.15 1.31 (0.91–1.88)
Bilirubin direct (per mol/l) 2.0 0.16 0.94 (0.86–1.03)
Long-acting nitrates (yes vs. no) 1.9 0.17 0.73 (0.46–1.14)
SBP (per mmHg) 1.9 0.17 1.01 (1.00–1.02)
Medical history: hypertension (yes vs. no) 1.9 0.17 1.31 (0.89–1.93)
Lymphocytes (per %) 1.6 0.21 1.01 (0.99–1.03)
Ejection fraction 1.5 0.22 0.48 (0.15–1.54)
MCHC (per mmol/l) 1.3 0.25 1.16 (0.90–1.48)
Basophils (per %) 1.2 0.27 1.32 (0.81–2.15)
Hemoglobin (per mmol/l) 1.2 0.28 1.11 (0.92–1.35)
NYHA (III or IV vs. I or II) 1.0 0.33 1.21 (0.83–1.76)
Medical history: prior myocardial
infarction (yes vs. no)
0.8 0.36 0.84 (0.59–1.21)
Alkaline phosphatase (per units/l) 0.8 0.38 1.00 (1.00–1.01)
Oral anticoagulant therapy (yes vs. no) 0.8 0.38 0.84 (0.56–1.25)
Hematocrit (%) 0.7 0.41 1.02 (0.98–1.06)
AST (per units/l) 0.6 0.44 1.00 (1.00–1.01)
Bilirubin total (per mol/l) 0.6 0.44 0.99 (0.96–1.02)
Sex (female vs. male) 0.3 0.58 1.11 (0.76–1.63)
Neutrophils (per %) 0.3 0.60 1.00 (0.98–1.01)
Monocytes (per %) 0.1 0.73 0.99 (0.92–1.06)
Calcium channel blocker (yes vs. no) 0.002 0.96 1.01 (0.66–1.55)
Smoking habit (current or past vs. none) 0.000 0.99 1.00 (0.67–1.49)
*Only factors with P  0.10 on univariate logistic regression were included in this multiple factor logistic regression. AST, aspartate aminotransferase; MCH, mean
corpuscularhemoglobin;MCHC,meancorpuscularhemoglobinconcentration;MCV,meancorpuscularvolume;NYHA,NewYorkHeartAssociationClassiﬁcation
of heart failure; SBP, systolic blood pressure.
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optimal point for diabetes prediction was
at a BMI of 29.1 kg/m
2, which yielded a
sensitivity of 0.73 and a speciﬁcity of
0.63. Of the other factors associated with
incident diabetes, serum ALT gave the
best AUC-ROC of 0.63 on univariate
analysis. Predictive performance was
moderately improved by the addition of
BMI to A1C in a multivariate model. The
AUC-ROC for BMI and A1C combined
was 0.79 with a sensitivity of 0.73 and
speciﬁcity of 0.72 for predicting incident
diabetes. Adding other elements associ-
atedwithfuturediabetes(digoxin,diuret-
ics and lipid-lowering therapies, lower
age, lower serum creatinine, and higher
ALT concentrations) to the model im-
proved AUC-ROC progressively, al-
though by relatively small amounts, to a
maximum of 0.82.
CONCLUSIONS — Analysis of data
from the CHARM program conﬁrmed the
high general prevalence and incidence of
diabetes in patients with CHF. An esti-
matedincidenceof21–28casesper1,000
patientsperyear(meanage66years)con-
trasts with the incidence of diabetes of
16.8 cases per 1,000 population per year
(age 65–79 years) and 11.2 cases per
1,000 population per year (age 45–64
years) from the National Health and Nu-
trition Examination Survey (NHANES) in
2003 (16) in which self-reporting of dia-
beteswasused.Dataavailablefrom1,620
of these patients in CHARM, of whom
126 developed diabetes, showed that the
two most powerful independent predic-
tors of diabetes in the program were A1C,
a measure of dysglycemia, and BMI. Both
gave AUC-ROCs very similar to those ex-
pected in the general population. Given
the worse outcomes of CHF events de-
scribed in patients with diabetes, the abil-
ity to better identify individuals at risk of
diabetes may allow the clinician to take
steps to reduce this risk with resultant
better clinical outcomes. In view of evi-
dence that A1C is a predictor of cardio-
vascular death, hospitalization, and total
mortality in not only diabetic but also
nondiabetic patients with CHF (17), its
measurement in patients with CHF may
have clinical potential, and future studies
thatincludefastingglucosewillallowfur-
ther assessment of this. This is on the
background of emerging support for the
use of A1C as part of a screening strategy
for diabetes (18).
The independent associations of cer-
tain characteristics with the development
of diabetes, namely use of lipid-lowering
therapy, use of digoxin, and lower serum
creatinine concentration, plus the strong
association of diuretic use at baseline re-
quire further examination and explana-
tion. With regard to baseline therapies,
there is contradictory evidence on statin
therapy and risk for incident diabetes
(19), which suggests that the association
found may reﬂect either ischemic heart
disease, itself associated with insulin re-
sistance, or underlying lipid abnor-
malities, which may predict diabetes
(hypertriglyceridemia and low HDL cho-
lesterol) rather than any statin treatment
effect. We are not aware of any data sug-
gesting that digoxin therapy inﬂuences
the development of diabetes. One possi-
bility is that patients receiving both
digoxin and diuretic therapies have more
severe CHF requiring more intensive
therapy, and, therefore, these are serving
as proxies of CHF severity. There is evi-
dence that worse CHF predicts diabetes
(20,21), although, interestingly, LVEF
did not predict diabetes in the present
analysis.Furtherstudiesareneededtoex-
amine these issues. Furthermore, there
are powerful data from the ﬁeld of hyper-
tension showing an increased incidence
of diabetes on diuretic therapy (22) rela-
tive to both placebo and other antihyper-
tensive agents. The proportions of
patientstakingloopandthiazidediuretics
in CHARM were not available. Those re-
ceiving multiple medications may have
had blood samples for biochemical anal-
yses taken more often outside the trial,
therebyincreasingthechanceofdetecting
diabetes if fasting glucose analyses were
also performed. As shown in CHARM
(12)andelsewhere,theuseofACEinhib-
itors and ARBs leads to a rise in serum
creatinineconcentration,andsothisﬁnd-
ing may reﬂect confounding effects of
treatments on diabetes risk rather than
anydirectassociationbetweenrenalfunc-
tion and diabetes risk. In addition, lower
creatinine concentrations could partially
reﬂect reduced muscle mass and thus a
biologically plausible mechanism linking
lower creatinine levels to elevated higher
diabetes risk.
The increase in risk of diabetes per
unit increase in serum ALT was admit-
tedlymodestandofuncertainclinicalsig-
niﬁcance in this analysis; furthermore,
elevation in serum ALT may occur as a
result of hepatic congestion in CHF.
However,itshouldberecognizedthatthe
association between serum ALT and risk
of diabetes concurs with ﬁndings in the
general population. Serum ALT, a hepa-
tocellular enzyme, is a reasonable marker
of fat accumulation in the liver in nonal-
coholic fatty liver disease (23). Nonalco-
holicfattyliverdiseaseisitselfacondition
strongly linked to insulin resistance, type
2 diabetes, and obesity. Serum ALT has
previously been shown to predict diabe-
tesindifferentpopulations,includinghy-
percholesterolemic men in Scotland (24)
and a general population cohort in Japan
(25), but to our knowledge this is the ﬁrst
evidence of any association in patients
with CHF. This ﬁnding implies that liver
fat is relevant to the pathogenesis of dia-
betes in patients with CHF, as it is in in-
dividuals without CHF.
The ﬁnding that younger age was an
independent predictor of diabetes was
unexpected. It may simply be that
younger patients with CHF have a longer
survival time and consequently a greater
chancetodevelopdiabetes.Analternative
explanation is that younger patients with
CHF may represent a slightly different
phenotype with higher BMI and higher
risk of diabetes compared with that of
older patients. There are data to support
this suggestion; in a substudy of 2,107
patients in CHARM, the prevalence of
Table 3—Multiple logistic regression of baseline characteristics with stepwise selection of all
effects predicting the development of diabetes in CHF
Wald 
2 P OR (95% CIs)
A1C 51.6 0.0001 1.78 (1.52–2.08)
BMI 26.6 0.0001 1.64 (1.36–1.98)
Lipid-lowering therapy 12.1 0.0005 2.05 (1.37–3.07)
Serum creatinine 9.7 0.0018 0.68 (0.54–0.87)
Diuretic therapy 8.6 0.0033 4.81 (1.69–13.69)
Digoxin therapy 5.2 0.0221 1.65 (1.08–2.54)
ALT 4.9 0.0269 1.15 (1.02–1.31)
Age 3.9 0.0476 0.81 (0.65–1.00)
ORs are expressed per 1 SD change in age, BMI, ALT, A1C, and creatinine.
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2) was four
times higher in patients with CHF aged
50 years than in patients aged 80
years (data not shown). Irrespective of
the above ﬁndings, it should be noted
that age did not signiﬁcantly improve
AUC-ROC for prediction beyond other
measures.
The strengths of the present analysis
are the number of incident cases of diabe-
tesandnumberofpatientsincludedinthe
program, together with excellent baseline
phenotyping. There are also potential
weaknesses that must be highlighted.
Giventhatidentifyingpredictorsofdiabe-
tes was not a predetermined outcome of
the CHARM program, these ﬁndings
must be treated as post hoc. In addition,
alldataarelimitedtoNorthAmericanpa-
tients. Ideally, the diagnoses of diabetes
would have been carried out uniformly
under controlled circumstances in all
patients, although pragmatic factors, as
occurs in clinical practice, dictated oth-
erwise. We cannot, therefore, exclude the
possibilitythatpatientswithundiagnosed
diabetes at baseline were included in our
analysis. It would also have been prefera-
bletomeasureandincludefastingglucose
results and serum lipids, particularly se-
rum triglycerides, but the patients were
nonfasting and so these parameters were
not available. Finally, potentially useful
data such as family history of diabetes
were not available. Nevertheless, the re-
sults provide the ﬁrst comprehensive ex-
amination of predictors of diabetes in
patients with CHF and provide a useful
framework for further study.
In summary, the strongest predictors
of development of diabetes in patients
with CHF in the CHARM program were
A1C and BMI, in line with prior observa-
tionsinthegeneralpopulation.Othermi-
nor independent predictors of diabetes in
part reﬂected CHF severity or drug-
associated diabetes risk, but their addi-
tion did not substantially improve
prediction of diabetes. Our ﬁndings sug-
gest that simple predictors would serve
welltoidentifythosepatientswithCHFat
elevated risk for developing type 2 diabe-
tes. Identiﬁcation of high-risk individuals
may allow application of approaches that
reduce progression to diabetes in patients
with CHF and potentially result in better
clinical outcomes.
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